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To the Editor,
We read with interest the article by Çölgeçen et al.
describing 46 cases of pediatric pityriasis rosea (PR) (1)
and we would like to make few observations and report
our experience.
The authors stated that the cause of PR is not known
(1) despite recent studies that established a causal role
for systemic active HHV-6 and HHV-7 infection in the
pathogenesis of PR. Indeed, HHV-6 and HHV-7 DNAs
were found in plasma and lesional skin by real-time
polymerase chain reaction (PCR) of patients with PR
and HHV-6 mRNA expression and specific antigens
by immunohistochemistry in their PR lesions (2–4).
Furthermore, herpesvirus virions in various stages of
morphogenesis were detected by electron microscopy in
skin lesions and in the supernatant of cocultured peripheral
blood mononuclear cells (PBMCs) from patients with PR
(5). Notably, HHV-6 and HHV-7 plasma viremia, a marker
of systemic active infection, was demonstrated in PR
patients and was related to the presence of constitutional
symptoms (2,4).
We agree with the authors that PR typically resolves
within 6–8 weeks (1), but recently relapsing (6) and
persistent (7) forms (lasting longer than 12 weeks) of PR
have also been reported in adults and children and these
forms are probably underestimated.
Çölgeçen et al. stated that few reports of pediatric PR
are currently available (1). However, in our series of 640
consecutive PR patients we collected 47 children (7%)
under 10 years of age (8). From 31 of them (19 females and
12 males with a mean age of 6.9 years) we obtained informed
parental consent to study clinical features and virological
parameters, comparing them with adult patients with PR.
In disagreement with Çölgeçen et al., who found a higher
prevalence of PR in winter (1), we found that pediatric
PR (8), like adult PR (9), occurs uniformly throughout
the year with no statistically significant differences, unlike
other infectious exanthems for which seasonal occurrence
* Correspondence: giuliaciccarese@libero.it

1302

Final Version: 23.08.2017

has been documented (10). Infections (exanthema
subitum, fifth disease, pharyngitis, and tonsillitis) and
drug intake (antibiotics) before skin manifestations were
recorded respectively in 23% and 6% of our patients,
significantly below the figure reported by Çölgeçen et al.
(1). Similar to Çölgeçen et al. (1), a herald patch (HP) was
found in most of our patients (58%), especially on the
trunk; the median time between appearance of HP and
secondary eruption was 4 days; and the skin eruption had
an average duration of 16 days. Unlike Çölgeçen et al. (1),
who did not observe oral lesions, we found in 35% of our
patients painless oropharyngeal lesions: vesicles were the
most common ones, followed by petechiae, papules, and
strawberry tongue. Regarding systemic symptoms, which
were not reported in Çölgeçen’s series (1), almost half of
our patients (48%) complained of systemic symptoms
during the course of PR (prodromal or accompanying
symptoms especially during the first 7 days from onset):
irritability was the commonest one, followed by headache,
fatigue, sore throat, and conjunctivitis. Conversely,
pruritus, experienced by 74% of the patients in Çölgeçen’s
series (1), was unremarkable in our patients. Interestingly,
15/46 (33%) patients studied by Çölgeçen et al. took drugs
before the appearance of PR (1). However, the authors
made no efforts to distinguish between genuine PR and
PR-like eruptions (usually drug-induced) according to the
criteria previously described (11).
Importantly, comparing the clinical features of children
with PR (including the patients of our series and that of
Çölgeçen et al.) with those of adult PR patients reported
in the literature (9), the occurrence of HP does not differ
greatly. By contrast, the mean time lapse between HP
and the generalized eruption in children (4 days) is very
short compared to adults (about 2 weeks), as well as the
exanthem duration, lasting about 2 weeks in children and
about 45 days in adults (ranging from 2 weeks to a few
months (7)). Oropharyngeal lesions, at least in our series,
appear to be commoner in PR children than in adults:
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we reported oral involvement in 35% of children, a rate
much higher than those reported in adult dark-skinned
(9%) (12) and Caucasian patients (16%) (9). Regarding
the occurrence of systemic symptoms, they are frequently
reported both in adults (69%) (9) and children with PR
(48%) (8).
Finally, we also compared our children PR patients
with adult PR patients from a virological point of view: we
collected blood samples at the first visit for specific antiHHV-6 and anti-HHV-7 serology and for the search for
HHV-6 and HHV-7 DNA loads in plasma and PBMCs
by calibrated quantitative real-time PCR (cq-PCR). For
12 children we also took blood samples 4–6 weeks after
recovery for the same investigations. Unfortunately, in
Çölgeçen’s series, virological investigations were not
performed. Our serological findings in children with PR
showed IgG antibody positivity against HHV-6 in 26 of

them (84%) and IgM antibodies only in 5 (16%). Serology
for HHV-7 revealed IgG antibodies in 19 patients (61%)
and IgM antibodies only in 3 cases (10%). In all cases,
the presence of high-avidity IgG antibodies allowed us
to rule out the possibility of a primary infection, thereby
confirming an HHV-6 and/or HHV-7 endogenous
systemic reactivation. cq-PCR demonstrated in all patients
HHV-6 and/or HHV-7 plasma viremia (8). Compared to
adult PR patients (4), both during the acute phase and 4–6
weeks after recovery, children showed a higher average
level of plasma viremia for both HHV-6 and HHV-7 (8).
In conclusion, our data point out that PR has different
clinical and virological features between adults and
children, suggesting that, following HHV-6 and/or HHV7 systemic reactivation, the pathogenetic mechanisms
involved in PR may be at least partially different in children
and adults.
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To the Editor,
We are most grateful to Drago et al. for their interest
in our paper entitled “Pityriasis rosea: a natural history
of pediatric cases in the Central Anatolia Region of
Turkey” (1). The basic aim of our study was to examine the
demographic, clinical, and epidemiological characteristics
of pityriasis rosea (PR) in children (1). That is why no
virological examination was performed.
While drugs, stress, pregnancy, and various infections
have previously been implicated in the etiopathogenesis of
PR, there has recently been focus on systemic activation of
human herpes virus (HHV)-6 and HHV-7 (2–8).
Drago et al. observed that pediatric PR appeared at
similar rates throughout the year (7), while we determined
a higher prevalence of PR in children in winter (1). The
fall in environmental temperatures may have triggered the
disease by suppressing cellular immunity in susceptible
individuals.
Drago et al. recorded various infections in 26% of
patients before skin manifestations in pediatric PR, and
drug use in 6% (7), while 32.6% of our patients had a
history of upper respiratory tract infection and 32.6% a
history of drug use (1). These levels were close to those
reported in Gündüz et al.’s study from Turkey (9).
PR-like eruption is defined as a medicationinduced cutaneous rash whose clinical characteristics
are remarkably similar to those of genuine PR, and that
often cannot easily be distinguished from it. However, it
is exceedingly important to do so, since typical PR may
occur during treatment, but independently of it. Various
differentiating criteria have recently been suggested.

Clinical, histopathological, and virological investigations
will certainly be useful in such differentiation (8,10).
However, even if virological investigations prove to
be useful in this area, they are nevertheless difficult to
implement in practice. Diagnosis of PR was based on
history and physical examination in the majority of our
cases. However, in atypical cases, skin biopsy performed
by a dermatologist was used in order to differentiate
between PR and other exanthemas. Patients with indefinite
diagnoses were considered for enrollment (1).
Pruritus has been reported in 25% of adult PR patients
and in 69%–90% of children. The incidence of pruritus
in our study was 74% (9,11,12). The incidence was higher
than the general figure reported for adults, but similar
to previous studies involving pediatric populations
(1,9,11,12).
Drago et al. observed oral involvement in 35% of
children with PR (7), while Amer et al. determined no oral
lesions in children of Afro-American origin (11). We also
observed no oral lesions in our patients (1). This suggests
that socioeconomic status and genetic factors may be
involved in the course of PR.
In conclusion, PR exhibits a similar course in children
and adults in Turkey. We observed a higher incidence
of disease during the rainy and snowy months. Upper
respiratory tract infection was determined prior to rash in
32.6% of our subjects. The high prevalence of pruritus also
constituted a significant finding, but this quickly resolved.
Further studies involving larger patient numbers are now
needed to compare PR symptoms between different age
cohorts and ethnic groups.

References
1.

Çölgeçen E, Kader Ç, Ulaş Y, Öztürk P, Küçük Ö, Balcı M.
Pityriasis rosea: a natural history of pediatric cases in the
Central Anatolia Region of Turkey. Turk J Med Sci 2016; 46:
1740-1742.

2.

Browning JC. An update on pityriasis rosea and other similar
childhood exanthems. Curr Opin Pediatr 2009; 21: 481-485.

* Correspondence: drecolgecen@hotmail.com

1304

3.

Canpolat Kirac B, Adisen E, Bozdayi G, Yucel A, Fidan I,
Aksakal N, Gurer MA. The role of human herpesvirus 6,
human herpesvirus 7, Epstein-Barr virus and cytomegalovirus
in the aetiology of pityriasis rosea. J Eur Acad Dermatol
Venereol 2009; 23: 16-21.

CICCARESE et al. / Turk J Med Sci
4.

Chuh AA, Chan HH. Prospective case-control study of
chlamydia, legionella and mycoplasma infections in patients
with pityriasis rosea. Eur J Dermatol 2002; 12: 170-173.

5.

Rajpara SN, Ormerod AD, Gallaway L. Adalimumab-induced
pityriasis rosea. J Eur Acad Dermatol Venereol 2007; 21: 12941296.

6.

Polat M, Yildirim Y, Makara A. Palmar herald patch in
pityriasis rosea. Australas J Dermatol 2012; 53: 64-65.

7.

Drago F, Ciccarese G, Broccolo F, Cozzani E, Parodi A.
Pityriasis rosea in children: clinical features and laboratory
investigations. Dermatology 2015; 231: 9-14.

8.

Drago F, Ciccarese G, Rebora A, Broccolo F, Parodi A. Pityriasis
rosea: a comprehensive classification. Dermatology 2016; 232:
431-437.

9.

Gündüz O, Ersoy-Evans S, Karaduman A. Childhood pityriasis
rosea. Pediatr Dermatol 2009; 26: 750-751.

10.

Drago F, Broccolo F, Agnoletti A, Drago F, Rebora A, Parodi A.
Pityriasis rosea and pityriasis rosea-like eruptions. J Am Acad
Dermatol 2014; 70: 196.

11.

Amer A, Fischer H, Li X. The natural history of pityriasis
rosea in black American children: how correct is the “classic”
description? Arch Pediatr Adolesc Med 2007; 161: 503-506.

12.

Stulberg DL, Wolfrey J. Pityriasis rosea. Am Fam Physician
2004; 69: 87-91.

1305

